Related Stocks: CEGE, DNDN Centient Biotech Investor submits: In a surprise move, an FDA advisory committee Thursday recommended approval of the cancer immunotherapy Provenge from Dendreon (DNDN). Complete Story »
Categories
- About Flood Insurance
- Allstate Insurance Claim
- Articles
- Blogroll
- Commercial Vehicle Insurance
- Credit Insurance Company
- Directories
- Disability Benefits Insurance
- Friends
- Gadgets
- Home Insurance
- House Insurance
- In Car Insurance
- In Dental Insurance
- Insurance Claims
- Insurance Companies
- Insurance News
- International Health Insurance
- Liability Insurance
- Life Insurance
- Medical Insurance
- Pet Insurance
- Progressive Insurance
- Reinsurance
- State Farm Insurance
- Sun
- Taxes
- Travel Insurance
- Usefull Resources
- Whole Life Insurance
Search
Latest
- Ex-Cologne Re exec was told deal involved no risk
- House again fails to override Bush’s SCHIP veto
- Blue Cross proposes fix for uninsured Americans
- Dodd urges Senate flood insurance action
- Congress approves bill to expand FMLA for military families
- EU adopts major energy, climate change plan
- Ambac posts $3.3 billion loss
- Reinsurer moves carbon trading desk to London
- Berkshire buys stake in Swiss Re
- Risk issues top WEF agenda
Responses to 'Will Dendreon’s Cancer Vaccine Win Final Approval?'